ACRODAT Prospective Evaluation Study
NCT: NCT04349839 · COMPLETED
Brief Summary
ACRODAT® is a new software medical device developed by a group of acromegaly experts to help practising endocrinologists assess disease activity in patients with acromegaly. It uses 5 key parameters (IGF-I level, tumour status, comorbidities, symptoms and Quality of life) to evaluate the patient's health status. The purpose of this post marketing surveillance study is to prospectively evaluate whether patients monitored by ACRODAT® with appropriate clinical decisions based on disease activity status will benefit from improved treatment outcomes both in the short and in the long term.
Frequently Asked Questions
What is ACRODAT Prospective Evaluation Study?
ACRODAT Prospective Evaluation Study is a clinical trial registered under NCT04349839. Current status: COMPLETED.
What is the status of NCT04349839?
The current status of NCT04349839 (ACRODAT Prospective Evaluation Study) is: COMPLETED.
When did ACRODAT Prospective Evaluation Study start?
ACRODAT Prospective Evaluation Study started on 2020-01-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.